Hangzhou Traditional Chinese Medicine Hospital
4
1
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 4 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (4)
The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy
Role: collaborator
Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial
Role: collaborator
An Investigation on the Role of Emergency Departments in Combatting Against COVID-19 in Zhejiang Province
Role: collaborator
Investigation on the Practice Status of Emergency Stuff
Role: collaborator
All 4 trials loaded